Clinical Trial Update: Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of SAM-531 in Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SAM-531

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED